Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Portage Biotech Inc ( (PRTG) ) has issued an announcement.
Portage Biotech Inc. announced receiving a noncompliance letter from Nasdaq due to insufficient shareholders’ equity, which currently does not affect the listing of its shares. The company plans to submit a compliance plan by January 24, 2025, to address this issue and potentially secure an extension to meet listing requirements. If not accepted, Portage may face delisting but intends to explore strategic alternatives to enhance its financial standing and market position.
More about Portage Biotech Inc
Portage Biotech Inc. is a clinical-stage immuno-oncology company that focuses on developing multi-targeted therapies aimed at extending survival and improving the lives of cancer patients. The company is exploring strategic alternatives and has made the decision to discontinue its iNKT program and pause its adenosine trial program.
YTD Price Performance: -89.53%
Average Trading Volume: 927,668
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $4.27M
For a thorough assessment of PRTG stock, go to TipRanks’ Stock Analysis page.
